Vistagen Therapeutics, Inc. Quarterly Common Stock, Shares Authorized from Q1 2011 to Q2 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
Vistagen Therapeutics, Inc. quarterly Common Stock, Shares Authorized history and growth rate from Q1 2011 to Q2 2024.
  • Vistagen Therapeutics, Inc. Common Stock, Shares Authorized for the quarter ending June 30, 2024 was 325M shares, unchanged year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 325M 0 0% Jun 30, 2024 10-Q 2024-08-13
Q1 2024 325M 0 0% Mar 31, 2024 10-Q 2024-08-13
Q3 2023 325M 0 0% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 325M 0 0% Jun 30, 2023 10-Q 2024-02-13
Q1 2023 325M 0 0% Mar 31, 2023 10-K 2024-06-11
Q4 2022 325M 0 0% Dec 31, 2022 10-Q 2023-02-07
Q3 2022 325M 0 0% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 325M 0 0% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 325M 0 0% Mar 31, 2022 10-K 2023-06-28
Q4 2021 325M +150M +85.7% Dec 31, 2021 10-Q 2022-02-10
Q3 2021 325M +150M +85.7% Sep 30, 2021 10-Q 2021-11-10
Q2 2021 325M +150M +85.7% Jun 30, 2021 10-Q 2021-08-12
Q1 2021 325M +150M +85.7% Mar 31, 2021 10-K 2022-06-23
Q4 2020 175M 0 0% Dec 31, 2020 10-Q 2021-02-11
Q3 2020 175M 0 0% Sep 30, 2020 10-Q 2020-11-12
Q2 2020 175M +75M +75% Jun 30, 2020 10-Q 2020-08-13
Q1 2020 175M +75M +75% Mar 31, 2020 10-K 2021-06-29
Q4 2019 175M +75M +75% Dec 31, 2019 10-Q 2020-02-13
Q3 2019 175M +75M +75% Sep 30, 2019 10-Q 2019-11-07
Q2 2019 100M 0 0% Jun 30, 2019 10-Q 2019-08-13
Q1 2019 100M 0 0% Mar 31, 2019 10-K 2020-06-30
Q4 2018 100M 0 0% Dec 31, 2018 10-Q 2019-02-12
Q3 2018 100M 0 0% Sep 30, 2018 10-Q 2018-10-29
Q2 2018 100M +70M +233% Jun 30, 2018 10-Q 2018-08-14
Q1 2018 100M +70M +233% Mar 31, 2018 10-K 2019-06-25
Q4 2017 100M +70M +233% Dec 31, 2017 10-Q 2018-02-12
Q3 2017 100M +70M +233% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 30M 0 0% Jun 30, 2017 10-Q 2017-08-14
Q1 2017 30M 0 0% Mar 31, 2017 10-K 2018-06-26
Q4 2016 30M 0 0% Dec 31, 2016 10-Q 2017-02-13
Q3 2016 30M 0 0% Sep 30, 2016 10-Q 2016-11-15
Q2 2016 30M +20M +200% Jun 30, 2016 10-Q 2016-08-12
Q1 2016 30M +20M +200% Mar 31, 2016 10-K 2017-06-29
Q4 2015 30M +20M +200% Dec 31, 2015 10-Q 2016-02-16
Q3 2015 30M +20M +200% Sep 30, 2015 10-Q 2015-11-16
Q2 2015 10M -190M -95% Jun 30, 2015 10-Q 2015-08-14
Q1 2015 10M 0 0% Mar 31, 2015 10-K 2016-06-24
Q4 2014 10M -190M -95% Dec 31, 2014 10-Q 2015-02-17
Q3 2014 10M -190M -95% Sep 30, 2014 10-Q 2014-11-19
Q2 2014 200M 0 0% Jun 30, 2014 10-Q 2014-08-12
Q1 2014 10M 0 0% Mar 31, 2014 10-K 2015-06-29
Q4 2013 200M 0 0% Dec 31, 2013 10-Q 2014-02-14
Q3 2013 200M 0 0% Sep 30, 2013 10-Q 2013-11-14
Q2 2013 200M 0 0% Jun 30, 2013 10-Q 2013-08-14
Q1 2013 10M -190M -95% Mar 31, 2013 10-Q 2014-11-19
Q4 2012 200M 0 0% Dec 31, 2012 10-Q 2013-02-14
Q3 2012 200M -200M -50% Sep 30, 2012 10-Q 2012-11-14
Q2 2012 200M -200M -50% Jun 30, 2012 10-Q 2012-08-14
Q1 2012 200M -200M -50% Mar 31, 2012 10-Q 2013-11-14
Q4 2011 200M Dec 31, 2011 10-Q 2012-02-14
Q3 2011 400M Sep 30, 2011 10-Q 2011-11-14
Q2 2011 400M Jun 30, 2011 10-Q 2011-08-22
Q1 2011 400M Mar 31, 2011 10-K 2012-07-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.